NEXALIN TECHNOLOGY INC. - COMMON STOCK

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

05 May 2025 08:20:19 By Nasdaq GlobeNewswire

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

01 May 2025 10:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

24 Apr 2025 09:00:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

23 Apr 2025 09:15:00 By Nasdaq GlobeNewswire

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

21 Apr 2025 08:00:00 By Nasdaq GlobeNewswire

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

14 Apr 2025 12:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

02 Apr 2025 08:30:00 By Nasdaq GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

26 Mar 2025 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

03 Mar 2025 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

28 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

26 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

18 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

10 Feb 2025 09:00:00 By Nasdaq GlobeNewswire

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

03 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

23 Jan 2025 11:00:00 By Nasdaq GlobeNewswire

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

14 Jan 2025 08:30:00 By Nasdaq GlobeNewswire

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

23 Dec 2024 10:00:00 By Nasdaq GlobeNewswire

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

26 Nov 2024 10:00:00 By Nasdaq GlobeNewswire

Nexalin Technology CEO Provides Letter to Shareholders

11 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

01 Nov 2024 14:00:00 By Nasdaq GlobeNewswire